• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

    4/30/25 7:30:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TGTX alert in real time by email

    NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.

    In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.

    TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

    ABOUT TG THERAPEUTICS

    TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline of investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.



    CONTACT:

    Investor Relations

    Email: [email protected]

    Telephone: 1.877.575.TGTX (8489), Option 4

    Media Relations:

    Email: [email protected]

    Telephone: 1.877.575.TGTX (8489), Option 6



    Primary Logo

    Get the next $TGTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TGTX

    DatePrice TargetRatingAnalyst
    10/29/2024$50.00Buy
    TD Cowen
    8/2/2023$16.00 → $12.00Sell → Neutral
    Goldman
    6/26/2023$55.00 → $40.00Buy
    Jefferies
    5/20/2022$5.00Underperform
    BofA Securities
    2/23/2022$49.00 → $35.00Buy
    B. Riley Securities
    1/28/2022$70.00 → $68.00Buy
    HC Wainwright & Co.
    1/24/2022$75.00 → $70.00Buy
    HC Wainwright & Co.
    12/1/2021$55.00 → $36.00Outperform
    Evercore ISI Group
    More analyst ratings

    $TGTX
    SEC Filings

    See more
    • TG Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)

      6/13/25 4:53:33 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by TG Therapeutics Inc.

      SCHEDULE 13G - TG THERAPEUTICS, INC. (0001001316) (Subject)

      5/13/25 12:23:32 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by TG Therapeutics Inc.

      10-Q - TG THERAPEUTICS, INC. (0001001316) (Filer)

      5/9/25 4:31:06 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care